A single-center, randomized, double-blind, placebo-controlled, single and multiple-dose phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HEC88473 injection in healthy subjects, obese subjects and subjects with type 2 diabetes
Latest Information Update: 24 Oct 2024
At a glance
- Drugs HEC 88473 (Primary)
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- 29 Dec 2023 New trial record
- 14 Nov 2023 Results presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases